The sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, was the subject of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) [31], the very first clinical trial to show supremacy for the primary endpoint. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.